摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7-amino-2,4-dioxo-5-(o-tolyl)-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carbonitrile | 365517-12-0

中文名称
——
中文别名
——
英文名称
7-amino-2,4-dioxo-5-(o-tolyl)-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carbonitrile
英文别名
7-amino-6-cyano-5-(2-methylphenyl)-5H-pyrano[2,3-d]pyrimidine-2,4(1H,3H)-dione;7-Amino-5-(2-methylphenyl)-2,4-dioxo-1,5-dihydropyrano[2,3-d]pyrimidine-6-carbonitrile
7-amino-2,4-dioxo-5-(o-tolyl)-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carbonitrile化学式
CAS
365517-12-0
化学式
C15H12N4O3
mdl
——
分子量
296.285
InChiKey
CTSDKJXCOGLNJP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1
  • 重原子数:
    22
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.13
  • 拓扑面积:
    117
  • 氢给体数:
    3
  • 氢受体数:
    5

反应信息

  • 作为产物:
    描述:
    巴比妥酸2-甲基苯甲醛丙二腈 在 1,10-(butane-1,4-diyl)bis(1H-benzo[d]imidazol-3-ium)hydrogen sulfate 作用下, 以 乙醇 为溶剂, 以94 %的产率得到7-amino-2,4-dioxo-5-(o-tolyl)-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carbonitrile
    参考文献:
    名称:
    三种新型纳米结构苯并咪唑基双阳离子布朗斯台德酸性熔盐的合成、表征和理化性质及其催化和抗菌活性比较
    摘要:
    在本研究中,合成了三种基于苯并咪唑的新型双阳离子 Brønsted 酸性熔盐,并通过 FT-IR、1 HNMR、13CNMR 和 FESEM 技术。应用分子中原子的拓扑分析(AIM)、电子局域化函数(ELF)、迈耶键指数和局部芳香性分析来研究所提出的熔盐分子的理论和电子结构,以及 CN、NH、NS 的性质、OH 和 H-Cl 键合进行了研究。通过琼脂井扩散法测试熔盐对枯草芽孢杆菌(革兰氏阳性)和大肠杆菌(革兰氏阴性)的抗菌活性。还使用两种不同介质(存在和不存在溶剂)中的两种不同的一锅多组分反应来评估新型盐的催化活性,以促进吡喃并 [2,3-d]-嘧啶酮的合成和聚氢喹啉衍生物。在这项研究中,研究了 H 0 ) 和电位滴定法) 及其对催化活性的影响。试剂容易制备、可重复使用、绿色工艺、后处理程序简单、收率高和反应时间短是这些盐类作为催化剂应用的最重要优点。
    DOI:
    10.1016/j.molliq.2021.117104
点击查看最新优质反应信息

文献信息

  • Comparison of the efficiency of two imidazole-based dicationic ionic liquids as the catalysts in the synthesis of pyran derivatives and Knoevenagel condensations
    作者:Zahra Sharifi、Nader Daneshvar、Mohaddeseh Safarpoor Nikoo Langarudi、Farhad Shirini
    DOI:10.1007/s11164-019-03874-5
    日期:2019.10
    ([C4(MIm)2]·2HSO4) were prepared via adequate, solvent-free methods and characterized using FT-IR, 1H NMR, 13C NMR, and potentiometric titration techniques. These reagents were investigated in the synthesis of 5-arylidene (thio)barbituric acids, 2-arylidene malononitriles, 4H-pyrans, and pyrano[2,3-d] pyrimidineones, and their catalytic activities were compared in the promotion of these reactions. Based
    在目前的工作中,使用3,3'-(1-丁烷1,4-丁二)双(1-甲基-1 H-咪唑-3-鎓)二化物([C 4(MIm)2 ]·2Cl)和3,通过适当的,无溶剂的方法制备了3 ' -(丁烷-1,4-二基)双(1-甲基-1 H-咪唑-3-鎓)硫酸氢盐[[C 4(MIm)2 ]·2HSO 4) FT-IR,1 H NMR,13 C NMR和电位滴定技术进行表征。在合成5-芳基(代)巴比妥酸,2-芳基丙二腈,4 H-喃和喃并[2,3- d]时对这些试剂进行了研究。比较嘧啶酮及其催化活性,以促进这些反应。根据获得的结果,我们发现[C 4(MIm)2 ]·2Cl在需要碱性或弱酸性介质的情况下显示出更高的催化效率。相反,在需要酸性催化剂以提高反应速率的反应中,[C 4(MIm)2 ]·2HSO 4是强大的催化剂。使用这些试剂,可以在较短的反应时间内,在温和,环保的条件下以优异的收率形成产物,而无需使用柱色谱进行后处理。
  • Three-component synthesis of 4<i>H</i>-pyran scaffolds accelerated by a gabapentin-based natural deep eutectic solvent
    作者:Meysam Alipour Khoshdel、Farhad Shirini、Mohaddeseh Safarpoor Nikoo Langarudi、Mehdi Zabihzadeh、Mohammad Biglari
    DOI:10.1039/d0nj05342b
    日期:——
    catalyst for the synthesis of 4H-pyran scaffolds such as tetrahydrobenzo[b]pyran and pyrano[2,3-d]pyrimidinone(thione) derivatives. The use of inexpensive and bio-compatible reagents for the synthesis of the catalyst, a simple and green procedure for the preparation of the catalyst and products, short reaction times, high yields of the products, and applicability to large-scale synthesis are the prominent
    在最近的有机合成中,对环境无害的合成方法的发展引起了越来越多的关注。作为这一概念的一部分,我们的小组使用加巴喷丁氯化胆碱合成了一种新型的天然深共熔溶剂(NADES)。在通过FTIR,1 H和13 C NMR以及质谱进行表征后,所制备的NADES被用作合成4 H-喃骨架如四氢苯并[ b ]喃和喃并[2,3- d ]的有效催化剂。]嘧啶酮(酮)衍生物。廉价的和生物相容性试剂用于催化剂的合成,用于催化剂和产物的制备的简单且绿色的过程,短的反应时间,产物的高产率以及适用于大规模合成是突出的问题。该协议的功能。而且,该催化剂可以容易地回收并循环多达五次,而不会显着损失其催化活性。
  • Zn[(L)proline]<sub>2</sub>: An Efficient Catalyst for the Synthesis of Biologically Active Pyrano[2,3-<i>d</i>]pyrimidine Derivatives
    作者:Majid M. Heravi、Azadeh Ghods、Khadijeh Bakhtiari、Fatemeh Derikvand
    DOI:10.1080/00397910903174390
    日期:2010.6.16
    derivatives were efficiently synthesized in excellent yields by a three-component, one-pot condensation reaction of malononitrile, benzaldehydes, and barbituric acid using a catalytic amount of Zn[(L)proline].
    通过丙二腈苯甲醛巴比妥酸的三组分、一锅缩合反应,使用催化量的 Zn[(L) 脯酸],以优异的收率高效合成了具有生物活性的喃并 [2,3-d] 嘧啶生物
  • Efficient synthesis of pyrano[2,3- d ]pyrimidinone and pyrido[2,3- d ]pyrimidine derivatives in presence of novel basic ionic liquid catalyst
    作者:Omid Goli Jolodar、Farhad Shirini、Mohadeseh Seddighi
    DOI:10.1016/s1872-2067(17)62827-4
    日期:2017.7
    ABSTRACT A basic ionic liquid, namely 1,1′-(butane-1,4-diyl)bis(1,4-diazabicyclo [2.2.2]octan-1-ium) hydroxide, was prepared and characterized using Fourier-transform infrared spectroscopy, 1H nuclear magnetic resonance spectroscopy, and pH measurements. The ionic liquid was used for efficient promotion of the synthesis of pyrano[2,3-d]pyrimidinone and pyrido[2,3-d]pyrimidine derivatives at room temperature
    摘要 制备了碱性离子液体,即 1,1'-(丁烷-1,4-二基)双(1,4-二氮杂双环 [2.2.2]octan-1-ium)氢氧化物,并使用傅里叶变换红外光谱对其进行表征。光谱、1H 核磁共振光谱和 pH 测量。该离子液体用于在室温研磨条件下有效促进喃并[2,3-d]嘧啶酮和吡啶并[2,3-d]嘧啶生物的合成。程序简单、反应时间短、收率高、非柱色谱分离、起始原料的商业可用性和催化剂的可回收性是该方法的吸引人的特征。
  • Ferric metformin drug complex supported on magnetic nanofiber cellulose; An efficient access to 4-H pyrans derivatives and determination of their antimicrobial activity
    作者:Firouz Matloubi Moghaddam、Maryam Daneshfar、Hamid Moghimi、Zahra Daneshfar
    DOI:10.1080/00397911.2022.2056850
    日期:2022.4.3
    ferric metformin and a novel nanocatalyst was prepared. This green heterogeneous organometallic catalyst was analyzed by physiochemical techniques. The new metformin drug complex supported on magnetic NFC was used as a powerful and efficient catalyst for the synthesis of functionalized 4H-pyrans derivatives. The antimicrobial activity of the products showed excellent activity against all the bacterial
    摘要 选择磁性纳米纤维纤维素(NFC)作为生物聚合物表面与二甲双胍反应,制备了新型纳米催化剂。通过物理化学技术分析了这种绿色多相有机属催化剂。以磁性 NFC 为载体的新型二甲双胍药物复合物被用作合成功能化 4H-吡喃生物的强大而高效的催化剂。产品的抗菌活性对所有细菌和真菌菌株(尤其是化合物7q和6r)均表现出优异的活性。
查看更多

同类化合物

叔-丁基2-(甲磺酰)-5,7-二氢螺[吡喃并[4,3-D]嘧啶并-8,3-吡咯烷]-1-甲酸基酯 乙基7'-氨基-6-氟-2,2',4'-三羰基-1,1',2,2',3',4'-六氢螺[吲哚-3,5'-吡喃并[2,3-d]嘧啶]-6'-羧酸酯 7H-吡喃并[2,3-d]嘧啶-7-酮 7H-吡喃并[2,3-d]嘧啶 7,8-二氢-5H-吡喃并[4,3-D]嘧啶-2-胺 5H-吡喃并[4,3-d]嘧啶 5H-吡喃并[2,3-d]嘧啶 2H-吡喃并[2,3-d]嘧啶-6-甲腈,7-氨基-1,3,4,5-四氢-5-(4-甲氧苯基)-2,4-二羰基- 2,4-二氯-7,8-二氢-5H-吡喃[4,3-d]嘧啶 1H-吡喃并[3,4-d]嘧啶 1H-吡喃并[3,2-d]嘧啶 (5S,7R,8S)-2-methylsulfanyl-5,8-dihydro-7-allyloxymethyl-5-methoxy-pyrano[3,4-d]-pyrimidin-8-ol 5-ethyl-2-[(Z)-1-thiophen-3-ylpentylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione 5-ethyl-2-[[1-(3-methylbutanoyl)piperidin-4-ylidene]amino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione 5-butyl-2-[(E)-1-(4-cyclohexylpiperazin-1-yl)butylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione 2,3,3a,9-tetrahydro-5-iodo-2,3,3-trimethylimidazo[5,1-b][1,3]benzoxazin-1-one 2,4-dimethyl-9-methoxy-4,12b-dihydro-1H,7H-chromeno[4',3'-4,5]pyrano[2,3-d]pyrimidine-1,3(2H)-dione 5-methyl-3-{3-[(R)-2-oxo-3-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)-oxazolidin-5-yl]-propyl}-1H-quinazoline-2,4-dione 7-amino-2-(benzothiazol-2-ylmethyl)-9-phenylthiazolo[4',5':6,5]pyrano[2,3-d]pyrimidine-8(7H)-one 2-[6-[(2-chlorophenyl)methyl]pyridin-2-yl]-7,8-dihydro-5H-pyrano[4,3-d]pyrimidine 8-amino-2-(methylthio)-5-oxo-6-(pyridin-4-yl)-5,6-dihydro-4H-pyrano[2,3-d][1,3]thiazolo[4,5-b]pyridine-7-carbonitrile 5-(4-chlorophenyl)-1,3,8,8-tetramethyl-7,9-dihydro-5H-chromeno[2,3-d]pyrimidine-2,4,6-trione ethyl 7'-amino-2,4'-dioxo-2'-thioxo-1,1',2,2',3',4'-hexahydrospiroindole-3,5'-pyrano[2,3-d]pyrimidine-6'-carboxylate 8-amino-2-(methylthio)-5-oxo-6-(pyridin-3-yl)-5,6-dihydro-4H-pyrano[2,3-d][1,3]thiazolo[4,5-b]pyridine-7-carbonitrile 7-Amino-4-oxo-5-phenyl-2-thioxo-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carboxylic acid ethyl ester 3-(1H-benzoimidazol-2-yl)-3-butyl-5-methyl-dihydro-furan-2-one 3-(1H-benzoimidazol-2-yl)-3-(2-diethylamino-ethyl)-5-methyl-dihydro-furan-2-one 1-{4-[(1R,9S)-3-((S)-3-methyl-morpholin-4-yl)-12-oxa-4,6-diaza-tricyclo[7.2.1.0-2,7]dodeca-2(7),3,5-trien-5-yl]-phenyl}-3-oxetan-3-yl-urea (S)-6-(4-(4-(3-ethylmorpholino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)phenylamino)pyridin-2(1H)-one 3-(1H-benzoimidazol-2-yl)-5-methyl-3-(3-methyl-butyl)-dihydro-furan-2-one 13-(3,4-dimethoxyphenyl)-5,5-dimethyl-2-thioxo-2,5,6,8,9,13-hexahydro-4H-pyrimido[5',4':6,7][1,8]naphthyridino[4,3,2-de]quinazoline-10,12(3a1H,11H)-dione (S)-3-allyl-8-ethyl-4,7-dioxo-2-(phenylcarbamoyl)-4,5,7,8-tetrahydro-3H-pyrano[4,3-d]pyrimidin-8-yl acetate 8-{[(2-bromo-3-methylphenyl)oxy]methyl}-1,3-dimethyl-2,3,4,6-tetrahydro-1H-pyrano[3,2-d]pyrimidine-2,4-dione 9-ethyl-6a-methyl-2-phenyl-8,9-dihydro-oxazolo[2,3-b]pyrimido[4,5-d][1,3]oxazin-5-one (S)-1-cyclobutyl-3-(4-(4-(3-methylmorpholino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)phenyl)urea (S)-2-(4-(4-(3-ethylmorpholino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)phenylamino)pyrimidin-4(3H)-one (6aRS,10aRS)-4,6,6a,7,8,9,10,10a-octahydro-2,4,6,6-tetramethyl-1H-<2>benzopyrano<3,4-d>pyrimidine-1,3(2H)-dione 5-ethyl-2-[(E)-1-thiophen-3-ylpentylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione N3-(methyl 4-deoxy-α-L-threo-hex-4-enopyranosyluronate)-5-fluorouracil 1-{4-[(1S,9R)-3-((S)-3-methyl-morpholin-4-yl)-12-oxa-4,6-diaza-tricyclo[7.2.1.0-2,7]dodeca-2(7),3,5-trien-5-yl]-phenyl}-3-oxetan-3-yl-urea 4,5-dimethyl-12-(4-methoxyphenyl)-2-thioxo-2,4a,7,8,9,10,11,12-octahydrodipyrimido[4,5-b;4',5'-f] [1,8]naphthyridine-9,11-dione 2-[4-[2-hydroxyethyl(methyl)amino]-2-methyl-7-oxopyrimido[5,4-b][1,4]oxazin-8-yl]acetonitrile 5-ethyl-2-[(Z)-1-thiophen-2-ylethylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione